Argus lifts Moderna to Buy after Phase III melanoma win for intismeran
AI Market Summary
Positive Phase III data for Moderna's personalized mRNA melanoma vaccine intismeran (with Merck's Keytruda) strengthens the company's oncology narrative and supports an accelerated path toward potential FDA approval around 2027. Argus upgraded MRNA on expectations of earlier stabilization and diversification away from COVID-era revenues, reinforcing bullish sell-side momentum despite some firms arguing the win was partly priced in.
Impact level
● Medium
Affected assets
NCSKMRNA2USD/USDT+0.06%
AI Insight · NCSKMRNA2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Moderna’s investigational drug intismeran reported positive results in a Phase III melanoma trial, and some oncologists expect it could reach the market as early as early 2027. Management updated its estimated timeline for a potential approval to 2027, bringing forward expectations for the company’s return to stable growth. Argus Research upgraded Moderna shares, saying “the tide is turning.”
